Which healing peptide has the strongest evidence?

GHK-Cu, for the topical route specifically. It is the only member of this ranking with a human trial that measured wound closure directly: Mulder 1994 found 98.5 percent median diabetic-ulcer closure against 60.8 percent for vehicle. BPC-157 ranks first on this page's live wound-healing subrating, 8.5–9.0/10, but its evidence base is preclinical-heavy, mostly animal and cell models rather than a human wound trial.

What is the difference between TB-500 and Thymosin Beta-4?

TB-500 is the synthetic 17-amino-acid fragment most peptide vendors sell, written as Ac-LKKTETQ. Thymosin Beta-4 is the full native 43-amino-acid peptide it is derived from, with its own separate human trial program including a Phase 1 IV safety study and ophthalmic Phase 2 and Phase 3 trials. They are ranked as two distinct reports on this page, TB-500 at 7.5–8.0/10 overall and Thymosin Beta-4 at 7.0–7.5/10, because they are genuinely different products with different evidence behind them.

Why isn't red light therapy or hyperbaric oxygen on this page?

This ranking is peptide-only by design. Red light therapy, hyperbaric oxygen, and ozone therapy all carry a scored wound-healing subrating too, but none of them is an amino-acid-chain compound, so they are devices and clinic procedures rather than peptides. They are ranked on the Recovery Devices and Therapies ranking instead, which covers non-peptide recovery tools.

Is KPV good for wound healing?

Its wound-healing subrating on this page, 3.5–4.0/10, sits near the bottom, narrowly above the category-fit floor. KPV's real strength is gut inflammation: the evidence behind it comes from murine colitis models through PepT1-mediated NF-kB suppression, not an external wound trial. Its overall score, 7.0–7.5/10, is mid-pack on this page, which is a genuine gap between what it is good at and what this specific page ranks on.

Why does AHK-Cu rank last?

Because it has the thinnest evidence on this page: one 2007 in-vitro and ex-vivo study and zero human trials of any kind. Its wound-healing subrating, 1.5–2.0/10, falls below this ranking's category-fit floor, computed from the top-ranked member's score. It keeps its row because it is a genuine published peptide report inside the category boundary, flagged rather than removed. Its close cousin GHK-Cu, one amino acid different, has the human data AHK-Cu lacks and ranks second on this page instead.

Is LL-37 safe to use for wound healing?

Use caution. Its only human wound data is one small 34-person trial where low doses helped and the highest dose failed against placebo. It also carries a documented double edge nothing else on this page has: it is a confirmed T-cell autoantigen in psoriasis and a growth factor for lung and ovarian cancer cells in laboratory studies. That combination is why it scores lowest overall on this page, 4.5–5.0/10, despite a real antimicrobial mechanism.

How often does this ranking change?

Whenever any member's wound-healing subrating changes. The order is the live BioHarmony subrating pulled from each report at render time, and a rescoring reorders the page that night. The likeliest mover is new human trial data, since most of this category's evidence is preclinical or mechanism-based rather than a completed human wound trial.

Category Ranking

Healing Peptides Ranked by Evidence

Which healing peptide actually works for wound closure and tissue repair?

Reviewed 09/23/2026

This page ranks by the live wound healing subrating, not the overall BioHarmony score. BPC-157 leads at 8.5–9.0/10, with GHK-Cu close behind at 8.0–8.5/10, backed by this category's only human trial measuring wound closure. KPV and AHK-Cu score lowest, and AHK-Cu falls below this ranking's category-fit floor.

BPC-157 wins wound healing at 8.5–9.0/10 and also carries a top overall score on the page, 7.5–8.0/10.
GHK-Cu ranks second at 8.0–8.5/10, and its topical route is the one human diabetic-ulcer trial with a directly measured wound-closure outcome in this category.
TB-500 and Thymosin Beta-4 are separately scored, related-but-distinct reports: the synthetic fragment (TB-500) ranks third on wound healing, the full native peptide (Thymosin Beta-4) ranks fourth.
AHK-Cu's wound-healing score, 1.5–2.0/10, sits below this ranking's category-fit floor. It keeps its row, flagged, not removed.
The order is live. When a member's wound-healing subrating changes, this page reorders with it.

The Ranking

7 interventions, ordered by their live Wound healing rating.

Scores are shown as a range because repeat scoring moves by up to ±0.8 on the 0-10 scale; printing one decimal would claim more precision than the method has. The order below is computed from the exact values, so two entries can share a range and still be ranked apart.

How this order works: Wound healing first, not the overall number

This page is ordered by each option's Wound healing rating: how well it works for that one goal, and nothing else.

The overall BioHarmony number beside it is a different measure. It weighs safety, cost, evidence and practicality across every goal an intervention is used for, so it answers "how good is this thing in general?" rather than "how good is it at this?".

That is why an option with a lower overall BioHarmony number can sit above one with a higher number here. It is the better choice for Wound healing, even though the other scores better taken as a whole.

Rank 1: BPC-157
Wound healing rating 8.5–9.0 / 10
Overall BioHarmony 7.5–8.0 / 10 🛡 Strong Recommend
First on wound healing at 8.5–9.0/10, and it also carries one of the highest overall scores on the page, 7.5–8.0/10. The evidence base is preclinical-heavy: Vasireddi 2025 reviewed 36 sports-medicine studies on BPC-157, 35 of them preclinical and one clinical, and no large human efficacy RCT exists as of the most recent audit. Sikiric 2018 and Seiwerth 2021 document the vascular-recruitment mechanism behind the wound-healing claim. It is inexpensive and widely used, and the honest asterisk is that the case still rests mostly on animal and cell models rather than a human wound trial.
Gastric pentadecapeptide, growth/repair peptide class. First on wound healing at 8.5–9.0/10, overall 7.5–8.0/10.
Read full BioHarmony report →
Rank 2: GHK-Cu
Wound healing rating 8.0–8.5 / 10
Overall BioHarmony 7.0–7.5 / 10 🛡 Strong Recommend
Second on wound healing at 8.0–8.5/10, one spot behind bpc-157, but it is the member with the strongest human evidence on this specific page. Mulder 1994 measured GHK-Cu against a vehicle control in diabetic foot ulcers and found 98.5 percent median wound closure against 60.8 percent for vehicle, a directly measured wound-closure outcome nothing else here has. The evidenced route is topical, not injectable: overall it sits at 7.0–7.5/10, and the injectable systemic version has no approved product and stays anecdotal.
Human copper-binding tripeptide, cosmetic/dermatologic peptide class. Second on wound healing at 8.0–8.5/10, overall 7.0–7.5/10.
Ranked above options with a higher overall BioHarmony number because it is stronger for Wound healing specifically.
Read full BioHarmony report →
Rank 3: TB-500 (Thymosin Beta-4 Fragment)
Wound healing rating 7.5–8.0 / 10
Overall BioHarmony 7.5–8.0 / 10 🛡 Strong Recommend
Third on wound healing at 7.5–8.0/10, and it ties bpc-157 for the highest overall score on the page, 7.5–8.0/10. TB-500 is the synthetic fragment sold as Ac-LKKTETQ, derived from thymosin beta-4 biology rather than the full native peptide ranked separately below. Its human evidence belongs mostly to the parent molecule: cell-migration work from Malinda 1997 and cardiac-repair signaling from Bock-Marquette 2004 describe the thymosin beta-4 mechanism this fragment is built to mimic, and musculoskeletal TB-500 use itself is preclinical plus community reports, not its own human trial.
Synthetic thymosin beta-4 fragment (Ac-LKKTETQ), growth/repair peptide class. Third on wound healing at 7.5–8.0/10, overall 7.5–8.0/10.
Read full BioHarmony report →
Rank 4: Thymosin Beta-4 (Tβ4)
Wound healing rating 4.5–5.0 / 10
Overall BioHarmony 7.0–7.5 / 10 🛡 Strong Recommend
Fourth on wound healing at 4.5–5.0/10, well behind the top three despite carrying a healthy overall score, 7.0–7.5/10. This is the full native 43-amino-acid peptide, distinct from the TB-500 fragment above, and it carries the most mature human data on this page outside GHK-Cu: a Phase 1 IV safety study in 40 healthy volunteers (Ruff 2010) with no dose-limiting toxicity, a Phase 2 wound trial in venous stasis ulcers (Guarnera 2007) showing a faster healing-initiation signal, and a Phase 3 hit in neurotrophic keratopathy (Sosne 2023) for the distinct ophthalmic formulation. None of that trial program targeted general soft-tissue wound healing directly, which is why the wound-healing score lands where it does despite the deeper evidence base.
Full native 43-amino-acid thymosin beta-4, growth/repair peptide class, distinct from the TB-500 fragment above. Wound healing 4.5–5.0/10, overall 7.0–7.5/10.
Read full BioHarmony report →
Rank 5: LL-37 (Cathelicidin)
Wound healing rating 4.0–4.5 / 10
Overall BioHarmony 4.5–5.0 / 10 🤷 Neutral
Fifth on wound healing at 4.0–4.5/10, and last overall on the page at 4.5–5.0/10. LL-37 is the only human cathelicidin antimicrobial peptide, and its human wound data is thin: one small first-in-human trial in 34 people with hard-to-heal venous leg ulcers (Gronberg 2014), where the lowest doses cut ulcer area about 68 and 50 percent and the highest dose did no better than placebo. Set against that is a genuine double edge: LL-37 is a documented T-cell autoantigen in psoriasis (Lande 2014) and a growth factor for lung and ovarian cancer cells (von Haussen 2008, Coffelt 2009), which is why it scores lowest overall despite a real antimicrobial and re-epithelialization mechanism.
Human cathelicidin antimicrobial peptide, immune peptide class. Wound healing 4.0–4.5/10, overall 4.5–5.0/10, the lowest overall on the page.
Ranked above options with a higher overall BioHarmony number because it is stronger for Wound healing specifically.
Read full BioHarmony report →
Rank 6: KPV (Lys-Pro-Val)
Wound healing rating 3.5–4.0 / 10
Overall BioHarmony 7.0–7.5 / 10 🛡 Strong Recommend
Sixth on wound healing at 3.5–4.0/10, narrowly above this ranking's category-fit floor, while carrying a mid-pack overall score on the page, 7.0–7.5/10. KPV's strongest evidence sits in gut inflammation rather than external wound closure: Dalmasso 2008 and Kannengiesser 2008 established the anti-inflammatory case in murine colitis models through PepT1-mediated uptake and NF-kB suppression, and Xiao 2017 extended that with a nanoparticle-delivery colitis model. Zero completed human RCTs exist for KPV in any indication, so its wound-healing position here is mechanism extrapolation from the same anti-inflammatory pathway, not a dedicated wound trial.
Alpha-MSH-derived tripeptide, immune peptide class. Wound healing 3.5–4.0/10, overall 7.0–7.5/10, clears the category-fit floor narrowly.
Read full BioHarmony report →
Rank 7: AHK-Cu (Copper Tripeptide)
Wound healing rating 1.5–2.0 / 10
Overall BioHarmony 6.5–7.0 / 10 Worth trying
Last on wound healing at 1.5–2.0/10, the only member on this page below the category-fit floor. AHK-Cu is a synthetic copper tripeptide, GHK-Cu's close cousin, differing by one amino acid, and it is marketed mostly for hair and cosmetic use rather than wound repair. Its evidence base is a single 2007 in-vitro and ex-vivo study (Pyo 2007) showing elongated hair follicles and increased dermal-papilla proliferation, and it has zero human trials of its own for any endpoint. Overall it sits at 6.5–7.0/10. It keeps its row on this page, flagged rather than removed, because it is a genuine published peptide report inside the category boundary even though the wound-healing case for it is the thinnest here.
Synthetic copper-binding tripeptide, cosmetic/dermatologic peptide class. Last on wound healing at 1.5–2.0/10, overall 6.5–7.0/10, below the category-fit floor, flagged not removed.
Read full BioHarmony report →

Best Pick by Use Case

Use Case	Winner	Runner-Up	Why
Wound Healing	BPC-157 8.5	GHK-Cu 8.0	The row the whole page is built around. BPC-157's 8.5–9.0/10 rests on a broad preclinical literature and one clinical safety pilot. GHK-Cu's 8.0–8.5/10 rests on the one human trial in this category with a directly measured wound-closure outcome, Mulder 1994's diabetic-ulcer data. Below those two the scores drop sharply: AHK-Cu (1.5–2.0/10) sits at the bottom.

At a Glance

Ranked

LL-37 (Cathelicidin)

4.5–5.0 / 10 ⚖️ Neutral

Upside · higher is better

Efficacy Moderate
Breadth Strong
Evidence Moderate
Speed Moderate
Durability Limited
Bioindividuality Moderate

Downside · lower is better

Safety Risk Moderate
Side Effects Moderate
Cost premium Moderate
Effort Moderate
Opportunity Cost Moderate
Dependency Low
Reversibility Low

Best at:

Wound Healing 4.2
Immune Function 3.7
Skin & Beauty 2.3
Anti-Inflammatory 2.2

Human cathelicidin antimicrobial peptide, immune peptide class. Wound healing 4.0–4.5/10, overall 4.5–5.0/10, the lowest overall on the page.

Read full BioHarmony report →

Ranked

AHK-Cu (Copper Tripeptide)

6.5–7.0 / 10 👍 Worth trying

Upside · higher is better

Efficacy Strong
Breadth Moderate
Evidence Moderate
Speed Moderate
Durability Limited
Bioindividuality Moderate

Downside · lower is better

Safety Risk Low
Side Effects Low
Cost premium Low
Effort Low
Opportunity Cost Moderate
Dependency Low
Reversibility Low

Best at:

Hair & Nail 2.8
Skin & Beauty 2.0
Wound Healing 1.8
Anti-Inflammatory 1.6

Synthetic copper-binding tripeptide, cosmetic/dermatologic peptide class. Last on wound healing at 1.5–2.0/10, overall 6.5–7.0/10, below the category-fit floor, flagged not removed.

Read full BioHarmony report →

Cost Comparison

Intervention	Monthly Cost	Notes
BPC-157	$40 to $80	Extracted from the report, priced 2026-09-08, gray-market research channel, at 250 to 500 mcg subcutaneous once or twice daily. Before syringes, bacteriostatic water, and third-party purity testing, which the report treats as necessary rather than optional.
GHK-Cu	$30 to $100	Extracted from the report, priced 2026-09-08, retail cosmetic channel, for a daily topical serum or cream, the route with the human outcome data behind it. Injectable vials run $60 to $150 a month and patch programs run $100 to $150, both anecdotal routes with no comparable evidence.
TB-500	$60 to $120	About $60 to $120 (estimate pulled from the report's own prose, since its cost data isn't fully filled in), gray-market research channel, for a 4 to 6 week loading phase at 2 to 2.5 mg subcutaneous twice weekly. Third-party certificate of analysis, HPLC purity, and endotoxin testing are called out in the report as the real hidden cost line most users underweight.
Thymosin Beta-4	$300 to $1,200	About $300 to $1,200 (estimate pulled from the report's own prose, since its cost data isn't fully filled in), research-grade channel, for a stacked 4 to 6 week recovery cycle including bacteriostatic water, syringes, and any clinician oversight. Genuine 43-amino-acid material runs $150 to $400 per vial, well above material mislabeled as TB-500, which does not deliver native Thymosin Beta-4.
LL-37	moderate, no report price range	Moderate, ongoing rather than extreme, since any benefit needs repeat dosing (estimate from the report's own prose; it gives no dollar figure to cite as a range).
KPV	$40 to $100	Extracted from the report, priced 2026-09-08, gray-market research channel, across oral, injectable, and intranasal routes at 250 to 500 mcg per day. Third-party testing and sterile supplies sit at the top of that band.
AHK-Cu	$74 to $115	About $74 to $115 (estimate), priced 2026-09-08, retail cosmetic channel, from comparable 4 percent copper-peptide serums at about 2 to 5 percent concentration for daily use. No dedicated AHK-Cu pricing exists since it is usually sold blended with GHK-Cu.

Who Should Pick What?

You have a soft-tissue injury and want the most-used option

BPC-157

It holds the top wound-healing score on this page and one of the highest overall scores, and it is inexpensive next to most regenerative-medicine options. The evidence is preclinical-heavy, so treat it as a targeted experiment with a defined endpoint rather than a proven clinical treatment.

You want the peptide with actual measured human wound-closure data

GHK-Cu

GHK-Cu is the only member on this page with a human trial that measured wound closure directly, Mulder 1994's diabetic-ulcer data. The evidenced route is topical. The injectable systemic version has no approved product and no comparable human data behind it.

You are deciding between TB-500 and Thymosin Beta-4

Tie

They are different products from the same biology. TB-500 is the synthetic fragment most peptide vendors sell and it ranks higher on wound healing here. Thymosin Beta-4 is the full native peptide with the deeper human trial program (a Phase 1 IV safety study, a Phase 2 wound trial, and a Phase 3 hit in a different indication), but none of those trials targeted general wound healing directly.

You are chasing gut inflammation more than an external wound

KPV (Lys-Pro-Val)

KPV's strongest evidence is in murine colitis models through PepT1-mediated NF-kB suppression, not external wound closure, which is why it ranks near the bottom of this specific wound-healing page despite a solid overall score. Zero completed human RCTs exist for it in any indication.

You are looking at LL-37 for a stubborn wound

BPC-157

LL-37's only human wound data is one small 34-person venous-leg-ulcer trial where the effective doses were low and the highest dose failed against placebo. It also carries a documented autoimmune and cancer double edge that every other member on this page lacks, which is why it scores lowest overall here. BPC-157 or GHK-Cu are the better-evidenced starting points for a stubborn wound.

You saw AHK-Cu marketed for hair or skin and wonder if it helps wounds

GHK-Cu

AHK-Cu has zero human trials for any endpoint, wound healing included, and it falls below this page's category-fit floor. Its close cousin GHK-Cu, one amino acid different, is the one with actual human data and ranks second on this page instead.

How This Ranking Is Built

Ranked by: Ranked by the live Wound healing rating (the Wound Healing subrating) This page is ordered by each option's Wound healing rating: how well it works for that one goal, and nothing else. The overall BioHarmony number beside it is a different measure. It weighs safety, cost, evidence and practicality across every goal an intervention is used for, so it answers "how good is this thing in general?" rather than "how good is it at this?". That is why an option with a lower overall BioHarmony number can sit above one with a higher number here. It is the better choice for Wound healing, even though the other scores better taken as a whole.
What is included: Every published BioHarmony intervention report that is an amino-acid-chain peptide compound (a signaling peptide, a growth or repair peptide, an antimicrobial or immune peptide, or a metal-binding cosmetic peptide) taken specifically to accelerate tissue repair, wound closure, or injury healing. Membership is carried by the compound's own peptide classification (growth-repair peptide, immune peptide, or cosmetic/dermatologic peptide) combined with a scored wound-healing subrating. Non-peptide healing modalities are explicitly excluded even when they carry the same wound-healing subrating: red light therapy, hyperbaric oxygen, and ozone therapy are devices and clinic procedures, not amino-acid-chain compounds, and they are ranked instead on the Recovery Devices and Therapies ranking. Adding a new peptide report inside this boundary adds a row.
Kept current: Positions and scores are read live from each intervention report on every page load, so the order re-renders the moment any member is rescored. Membership is rebuilt nightly against the inclusion rule above.

Ranked by the live Wound Healing subrating, read from each member's report when the page renders, not by the overall BioHarmony score. Wound healing is the goal both target search terms name directly, so this page orders on it rather than on a whole-report average that blends in goals nobody reading this page is asking about. The overall score still shows on every row, labeled separately, because it tells you how the member does across every goal this class of peptide is used for, not just this one. It never sets the order here.

This page is scoped to amino-acid-chain peptide compounds only. Non-peptide healing tools that also carry a wound-healing subrating, red light therapy, hyperbaric oxygen, and ozone therapy, are deliberately excluded and ranked instead on the Recovery Devices and Therapies ranking. That split is the reason this page exists as its own ranking rather than folding into the broader recovery category: a reader searching specifically for peptides gets a peptide-only answer.

TB-500 and Thymosin Beta-4 are two separately published, separately scored reports rather than one entry with two names. TB-500 is the synthetic 17-amino-acid fragment sold as Ac-LKKTETQ. Thymosin Beta-4 is the full native 43-amino-acid peptide it is derived from. They are ranked as distinct members because the underlying products, evidence bases, and regulatory histories differ even though the community frequently conflates them.

AHK-Cu is flagged by the advisory category-fit check, because its wound-healing subrating falls under this ranking's category-relative floor, computed as the greater of 2.0 or 40 percent of the top-ranked member's score, currently 8.5–9.0/10 times 0.4. That check measures how well a member's own scoring fits the goal this page ranks on, not whether it belongs to the category, so it removes nobody and AHK-Cu keeps its row. KPV clears the same floor, but narrowly.

Costs are estimates with a pricing date, drawn from each report's own cost record where one exists. TB-500, Thymosin Beta-4, and LL-37 have thinner cost data on file; their cost rows below are pulled from the report's own prose rather than invented, and each row says so.

Research Highlights

Mechanism Difference
Two very different repair signals sit inside this one category, and confusing them is the most common mistake. BPC-157, TB-500, and Thymosin Beta-4 work through nitric oxide, VEGFR2-linked angiogenesis, and G-actin-mediated cell migration, a growth and repair signaling class. LL-37 and KPV are immune peptides: LL-37 disrupts microbial membranes and recruits immune cells, and KPV suppresses NF-kB and MAPK inflammatory signaling through the PepT1 transporter. GHK-Cu and AHK-Cu are copper-binding cosmetic tripeptides that deliver copper as an enzymatic cofactor for collagen and elastin cross-linking, a mechanism closer to skincare chemistry than to systemic repair pharmacology.
Safety Comparison
Cancer caution runs through nearly every member of this category, because the same pro-repair, pro-angiogenic signal that heals tissue can also feed a tumor. BPC-157 and GHK-Cu both name active malignancy as a contraindication for exactly this reason. Thymosin Beta-4 carries a specific preclinical signal, rodent overexpression models showing it promotes melanoma migration and lung metastasis (Cha 2003), with correlative human tissue data in colorectal and pancreatic cancer (Oh 2016). LL-37 carries the same concern in its most documented form: it is a confirmed growth factor for lung cancer cells (von Haussen 2008) and drove ovarian tumor progression in a mouse model where neutralizing it slowed growth (Coffelt 2009).LL-37 carries a second edge nothing else here has. It is a documented T-cell autoantigen in psoriasis (Lande 2014) and implicated in lupus, rheumatoid arthritis, and atherosclerosis (Kahlenberg 2013), which is why its overall score is the lowest on this page even though its antimicrobial mechanism is real.
Cost Comparison
Cost on this page tracks legitimacy more than it tracks effect. GHK-Cu and AHK-Cu are the two members sold as ordinary OTC cosmetics, and they are also two of the cheaper lines here. Everything else is a gray-market research-peptide purchase, where the quoted price understates the real cost: a third-party certificate of analysis, HPLC purity testing, and endotoxin checks are named as necessary, not optional, on the BPC-157, TB-500, and KPV reports specifically.Thymosin Beta-4 is the outlier on price, running several times what TB-500 costs, because genuine 43-amino-acid material is harder to source correctly than the shorter fragment sold under the TB-500 name. That gap is a purity and molecule-identity problem, not a difference in demonstrated effect.
Evidence Maturity
GHK-Cu is the one member on this page with a human trial that measured wound closure directly. Mulder 1994 found 98.5 percent median ulcer closure against 60.8 percent for vehicle in diabetic patients, a real clinical outcome. Everything else here leans on preclinical models, mechanism plausibility, or trials that measured a different endpoint entirely: Thymosin Beta-4's Phase 1 and Phase 2 programs establish safety and a wound-initiation signal, not general wound-healing efficacy, and BPC-157's 36-study review found 35 of them preclinical.LL-37 and AHK-Cu sit at the thin end of that spectrum. LL-37 has one 34-person topical ulcer trial. AHK-Cu has a single 2007 in-vitro and ex-vivo study and zero human trials of its own, which is the practical reason it sits at the bottom of this ranking below the category-fit floor.
Editorial Verdict
For most soft-tissue and skin-repair goals, BPC-157 and GHK-Cu are the two peptides on this page with the strongest case behind them, for different reasons. BPC-157 has the largest and most consistent preclinical literature and a low cost. GHK-Cu has the one human trial here that actually measured wound closure, and it is available as an ordinary OTC cosmetic rather than a gray-market vial.TB-500 and Thymosin Beta-4 are worth understanding as two different products rather than one interchangeable name. LL-37 and AHK-Cu carry the thinnest human evidence on this page, and LL-37 carries a real safety double edge on top of that. KPV's case is strongest for gut inflammation, not the external wound closure this specific page ranks on, which is the honest reason it sits mid-table here despite a solid overall score.
Ranking Stability
This ranking is not an opinion refreshed on a schedule. The order is the live wound-healing subrating for each member, resolved when the page loads, so a rescoring of any one report reorders the page that night without an editorial pass.The realistic mover here is new human trial data, since most of this category's literature is preclinical or mechanism-based. A completed human wound trial for BPC-157, TB-500, or KPV, or an updated FDA compounding decision for Thymosin Beta-4, would be the kind of event that moves this page.

Frequently Asked Questions

Which healing peptide has the strongest evidence?: GHK-Cu, for the topical route specifically. It is the only member of this ranking with a human trial that measured wound closure directly: Mulder 1994 found 98.5 percent median diabetic-ulcer closure against 60.8 percent for vehicle. BPC-157 ranks first on this page's live wound-healing subrating, 8.5–9.0/10, but its evidence base is preclinical-heavy, mostly animal and cell models rather than a human wound trial.
What is the difference between TB-500 and Thymosin Beta-4?: TB-500 is the synthetic 17-amino-acid fragment most peptide vendors sell, written as Ac-LKKTETQ. Thymosin Beta-4 is the full native 43-amino-acid peptide it is derived from, with its own separate human trial program including a Phase 1 IV safety study and ophthalmic Phase 2 and Phase 3 trials. They are ranked as two distinct reports on this page, TB-500 at 7.5–8.0/10 overall and Thymosin Beta-4 at 7.0–7.5/10, because they are genuinely different products with different evidence behind them.
Why isn't red light therapy or hyperbaric oxygen on this page?: This ranking is peptide-only by design. Red light therapy, hyperbaric oxygen, and ozone therapy all carry a scored wound-healing subrating too, but none of them is an amino-acid-chain compound, so they are devices and clinic procedures rather than peptides. They are ranked on the Recovery Devices and Therapies ranking instead, which covers non-peptide recovery tools.
Is KPV good for wound healing?: Its wound-healing subrating on this page, 3.5–4.0/10, sits near the bottom, narrowly above the category-fit floor. KPV's real strength is gut inflammation: the evidence behind it comes from murine colitis models through PepT1-mediated NF-kB suppression, not an external wound trial. Its overall score, 7.0–7.5/10, is mid-pack on this page, which is a genuine gap between what it is good at and what this specific page ranks on.
Why does AHK-Cu rank last?: Because it has the thinnest evidence on this page: one 2007 in-vitro and ex-vivo study and zero human trials of any kind. Its wound-healing subrating, 1.5–2.0/10, falls below this ranking's category-fit floor, computed from the top-ranked member's score. It keeps its row because it is a genuine published peptide report inside the category boundary, flagged rather than removed. Its close cousin GHK-Cu, one amino acid different, has the human data AHK-Cu lacks and ranks second on this page instead.
Is LL-37 safe to use for wound healing?: Use caution. Its only human wound data is one small 34-person trial where low doses helped and the highest dose failed against placebo. It also carries a documented double edge nothing else on this page has: it is a confirmed T-cell autoantigen in psoriasis and a growth factor for lung and ovarian cancer cells in laboratory studies. That combination is why it scores lowest overall on this page, 4.5–5.0/10, despite a real antimicrobial mechanism.
How often does this ranking change?: Whenever any member's wound-healing subrating changes. The order is the live BioHarmony subrating pulled from each report at render time, and a rescoring reorders the page that night. The likeliest mover is new human trial data, since most of this category's evidence is preclinical or mechanism-based rather than a completed human wound trial.

Evidence Sources

Systematic review 2025 Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review Reviewed 36 sports-medicine studies on BPC-157, 35 preclinical and one clinical. No large human efficacy RCT found. The anchor for bpc-157's wound-healing and overall scores.
Review 2018 Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157: Vascular Recruitment and Gastrointestinal Tract Healing Describes the vascular-recruitment and cytoprotective mechanism behind BPC-157's wound-healing claim.
Review 2021 Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Reviews BPC-157's wound-healing evidence base across preclinical models.
RCT 1994 Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper 98.5 percent median diabetic ulcer closure with GHK-Cu against 60.8 percent for vehicle. The only member on this page with a human trial measuring wound closure directly.
Review 2015 GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration Reviews GHK-Cu's collagen, elastin, and antioxidant gene-signaling mechanisms in skin.
In vitro 1997 Thymosin beta-4 stimulates directional migration of human umbilical vein endothelial cells Foundational cell-migration mechanism shared by TB-500 (the fragment) and Thymosin Beta-4 (the native peptide).
Animal study 2004 Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Mouse post-MI model showing the migration and repair mechanism underlying both TB-500 and Thymosin Beta-4 reports.
RCT 2010 Phase 1 randomized, placebo-controlled, single and multiple-dose intravenous study of Thymosin Beta-4 in healthy volunteers 40 healthy volunteers, 42 to 1,260 mg/day IV for 14 days, no dose-limiting toxicity, no serious adverse events. The deepest human safety data on this page outside GHK-Cu.
RCT 2007 European prospective randomized Phase 2 trial of topical Thymosin Beta-4 (RGN-137) in venous stasis ulcers Acceptable safety and a mid-dose signal of faster wound-healing initiation. The closest thing to a dedicated human wound trial for the Thymosin Beta-4 arm.
RCT 2023 SEER-1 Phase 3 randomized, double-masked, placebo-controlled trial of 0.1 percent RGN-259 in neurotrophic keratopathy Significant promotion of complete corneal epithelial healing. A Phase 3 hit for the distinct ophthalmic Thymosin Beta-4 formulation, not general wound healing.
Animal study 2003 B16-F10 melanoma cells overexpressing Thymosin Beta-4 show increased migration, tumor vascularity, and lung metastatic nodules Preclinical cancer-metastasis signal behind the malignancy contraindication on the Thymosin Beta-4 report.
Observational 2016 High tumor Thymosin Beta-4 expression correlates with worse recurrence-free and overall survival in human colorectal cancer Correlative human tissue data supporting the same cancer caution as the rodent metastasis model.
RCT 2014 Topical LL-37 was safe and healed hard-to-heal venous leg ulcers in a first-in-human trial 34-person trial. Lowest doses cut ulcer area about 68 and 50 percent; highest dose no better than placebo. LL-37's only human wound-closure data.
Observational 2014 LL-37 is a T-cell autoantigen in psoriasis About 46 percent of psoriasis patients have circulating T cells that recognize LL-37. Part of why LL-37 scores lowest overall on this page.
In vitro 2008 LL-37 acts as a growth factor for lung cancer cells Increased lung cancer cell proliferation at 5 ng/mL via EGFR signaling. One half of LL-37's documented cancer double edge.
Animal study 2009 Pro-inflammatory LL-37 promotes ovarian tumor progression Neutralizing LL-37 inhibited tumor growth in a mouse model. The other half of LL-37's cancer double edge.
Animal study 2008 PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation Foundational murine colitis mechanism paper behind KPV's anti-inflammatory scoring, the strongest evidence KPV has, which is gut-focused rather than external wound-focused.
Animal study 2008 Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Confirms the anti-inflammatory mechanism in a second murine IBD model.
Animal study 2017 Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Nanoparticle-delivery colitis model extending KPV's preclinical evidence base. Zero completed human RCTs exist for KPV in any indication.
In vitro 2007 AHK-Cu tripeptide-copper complex elongated human hair follicles ex vivo and increased dermal-papilla cell proliferation in vitro The single existing AHK-Cu study, in vitro and ex vivo only. No human trial exists, the reason AHK-Cu falls below this ranking's category-fit floor.
Observational 2006 Topical copper tripeptide complex on CO2 laser-resurfaced skin reduced erythema Human observational data on a copper-tripeptide formulation, cited on the AHK-Cu report though closer to the better-studied GHK-Cu cousin.

Glossary

Quick reference for the medical and technical terms used in this comparison.

BPC-157 Body Protection Compound 157: A 15-amino-acid gastric pentadecapeptide fragment, the top-ranked member on this page, with a preclinical-heavy evidence base for tissue repair and angiogenesis.
GHK-Cu Copper Tripeptide-1: A human copper-binding tripeptide (glycyl-L-histidyl-L-lysine plus copper) with the strongest human wound-closure evidence on this page, at the topical route.
AHK-Cu Copper Tripeptide-3: A synthetic copper-binding tripeptide, one amino acid different from GHK-Cu, with a single in-vitro and ex-vivo study and no human trials. Below this page's category-fit floor.
TB-500 Thymosin Beta-4 fragment: The synthetic 17-amino-acid fragment Ac-LKKTETQ, sold under the TB-500 name, distinct from the full native peptide ranked separately on this page.
Tβ4 Thymosin Beta-4: The full native 43-amino-acid actin-sequestering peptide TB-500 is derived from, with its own separate human trial program including ophthalmic Phase 2 and Phase 3 trials.
LL-37 Cathelicidin: The only human cathelicidin antimicrobial peptide, with a real membrane-disruption and wound-repair mechanism alongside a documented autoimmune and cancer double edge.
KPV Lysine-Proline-Valine: A tripeptide derived from alpha-MSH amino acids 11-13, with its strongest evidence in gut-inflammation models rather than external wound healing.
PepT1 Peptide Transporter 1: The intestinal peptide transporter that imports KPV, making oral and rectal routes mechanistically coherent for gut use.
VEGFR2 Vascular Endothelial Growth Factor Receptor 2: A key angiogenesis receptor implicated in BPC-157's wound-healing mechanism.
COA Certificate of Analysis: Third-party HPLC and mass-spec verification of a research-peptide vial's actual identity and purity, named as necessary rather than optional on the gray-market members of this page.
Category-fit floor Minimum evidence bar for this page: 40 percent of the top-ranked member's wound-healing score on this page. A member scoring below it keeps its row, flagged, rather than being removed, so readers can see thin evidence rather than have it hidden.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

Nick's personal ratings. These are separate from the BioHarmony score, which is computed from the research.

I have spent over a decade testing performance and longevity interventions on myself and screening them for clients and podcast guests

Reviewed Sep 23, 2026

Find which one fits your biology

Take the BioHarmony Quiz

The Ranking

Rank 1: BPC-157

Rank 2: GHK-Cu

Rank 3: TB-500 (Thymosin Beta-4 Fragment)

Rank 4: Thymosin Beta-4 (Tβ4)

Rank 5: LL-37 (Cathelicidin)

Rank 6: KPV (Lys-Pro-Val)

Rank 7: AHK-Cu (Copper Tripeptide)